U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07732023) titled 'A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma' on July 19.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled phase Ib study to evaluate the safety, tolerability, efficacy, PK/PD characteristics, and immunogenicity of SKB575 (HBM7575) injection in subjects with asthma.
Study Start Date: July 20
Study Type: INTERVENTIONAL
Condition:
Asthma (Diagnosis)
Intervention:
DRUG: SKB575
Subcutaneous
DRUG: Placebo
Subcutaneous
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sichuan Kelun-Biotech ...